Photo from Paolo Tarantino/X
May 20, 2024, 13:27
Paolo Tarantino: A true honor to join the Executive Scientific Committee of the ENA Triple Meeting 2024
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn by EORTC – European Organisation for Research and Treatment of Cancer, adding:
“It was a true honor to have the chance to join the Executive Scientific Committee of the ENA Triple Meeting 2024, which unites EORTC, NCI and AACR into three days of new data, education and insights on the future of oncology, with an all star faculty.
Register by May 29 for the early rate, and make sure to join us in Barcelona!
Preliminary program here.”
Quoting EORTC – European Organisation for Research and Treatment of Cancer’s post:
“ENA 2024: DEADLINE ALERT: EARLY RATE REGISTRATION 29 May
Addressing the complex process of drug development, the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics delves into preclinical and clinical studies, driving progress in molecularly targeted therapies.
REGISTER NOW!”
REGISTER NOW!”
Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.
Jun 30, 2024, 11:37